

ANNUAL REPORT 2017









On behalf of the Perkins, thank you for your support in 2017.

I'd like to start by extending my heartfelt thanks to our staff, donors and supporters for another successful year. Throughout 2017, a strong focus on community building has enabled the Perkins to realise many major accomplishments.

Our annual flagship events – the MACA Ride to Conquer Cancer and the Hawaiian Walk for Women's Cancer – saw participants challenge themselves in support of medical research at the Perkins, and ultimately raise more than \$5 million collectively. Each year I am moved by the thousands of men and women who ride, walk and tirelessly fundraise for the Perkins.

Thank you to those who attended the Perkins 2017 Open Day, the Wesfarmers' Harry Perkins Oration, enrolled in workshops at the Lotterywest BioDiscovery Centre, or visited the institute for weekly research seminars or for tours of the state-of-the-art facility.

Thanks as well to the Perkins heart campaign ambassadors; Dennis Cometti, Dr Ric Charlesworth AO, The Hon. Wayne Martin AC, and John Inverarity MBE.

Having the heart campaign backed by these WA leaders rallied local philanthropists towards ensuring the success of the campaign.

Funds raised are contributing to the formation of an innovative hub of ground-breaking heart research in WA.

Towards the end of the year, we undertook some major changes in the research support structure, including multiple new appointments within our senior executive team. The experience and knowledge these new leaders bring to the institute will support the delivery of our strategic priorities over the coming years.

Under the tireless and dedicated leadership of Professor Peter Leedman, the Perkins has prospered as a world-class medical research institute and a key pillar of the WA health sector. Thank you sincerely to Peter and his team of dedicated staff and researchers.

We farewelled Professor John Challis from our Board at the end of 2017. We thank John for his great contribution to the Institute and to the State's medical research capability in general, serving as he did as the inaugural Executive Director of the WA Health Translation Network.

We welcomed Professor Dawn Freshwater, Vice-Chancellor of the University of WA to the Board in June 2017 and are benefitting from her wide experience.

I would like to warmly thank our Board of Directors who generously volunteer their time and expertise to guide the Perkins towards realising its vision of delivering better health outcomes for families.

Mr Laurence Iffla Chairman





It is my great privilege to report to you on the achievements of the Harry Perkins Institute of Medical Research in 2017.

It has been a remarkable year for our research groups, supporters and local community.

The Perkins has continued its excellent record of research success, with new grants, publication impacts and major awards confirming our position as one of the nation's leading research bodies.

Highlights for the year include:

- We recruited Professor Girish Dwivedi to take up the inaugural position of Wesfarmers' Chair in Cardiology. We are thrilled to be able to bring Professor Dwivedi's expertise to Perth, both in treating patients locally and improving research to accurately predict which patients may suffer a heart attack.
- Perkins Deputy Director, Professor Peter Thompson, co-led a major trial involving 5,000 patients on the use of a low dose anti-inflammatory drug (Colchicine) for preventing heart attacks.
- Perkins acquired funding to establish a ground breaking new genome sequencing centre for the state, led by Professor Alistair Forrest, to transform cancer research in Western Australia.

- Perkins researcher, Associate Professor Kevin Pfleger, co-led the launch of a new training centre to accelerate the development of new therapies.
- More than 500 people, including cancer patients, participated in 49 trials at our clinical trials facility, Linear Clinical Research Ltd.
- We made multiple key discoveries about the role of the immune system and cancer, devised new ways to treat some cancers, discovered the underlying genetic cause for some muscle diseases, discovered a new gene associated with obesity, identified new tiny microRNA signatures associated with cancer and cardiovascular disease, and have played a major role in several biomedical engineering projects to directly improve patient outcomes with cancer and large vessel disease.

We are justly proud of our researchers and staff for their exceptional efforts in 2017.

Thank you to each and every donor and supporter who contributes to research at the Perkins, sustaining our success in delivering lasting health benefits. Without you, our work simply wouldn't be possible.

Professor Peter Leedman

Director



PERKINS YEAR IN REVIEW

research & trial staff and students







significant scientific discoveries



presentations to state, national and international forums



trials awarded to Linear Clinical Research





new collaborations between researchers

attendees to **BioDiscovery** workshops





consumer buddies paired

new research grants and fellowships





steps to defeat breast and ovarian cancer in the Hawaiian Walk for Women's Cancer





190,000

kilometres cycled by **MACA Ride to Conquer** Cancer participants



schools completed BioDiscovery programs


2017 MAJOR ACHIEVEMENTS



JANUARY

Professor Nigel Laing AO and Dr Gina Ravenscroft receive prestigious five-year and four-year fellowships respectively from the NHMRC to study neurogenetic diseases.

Click to read full story



FEBRUARY

A landmark study mapping a poorly understood and highly controversial class of genes, known as long non-coding RNAs, found evidence of evolutionary selection and links with major diseases, including cancer.

Click to read full story




MARCH

Major clinical trial into the use of a gout medicine in preventing heart attacks commenced.

Click to watch 7 News report

Perkins medical entrepreneur, A/Professor Kevin Pfleger, wins 40under40 award. Click to read full story



APRIL

New ground-breaking technique to identify specific bacteria causing infections announced. Click to read full story

Contributed to an improved method of diagnosing genetic muscle diseases.

Click to read full story

Wesfarmers Chair in Cardiovascular Disease appointed. Click to read full story



MAY

500 incredible walkers raised \$1 million for women's cancer research at the Perkins. Click to read full story

Perkins researcher, Professor Ryan Lister, appointed as an HHMI International Research Scholar. Click to read full story

Professor Peter Leedman joined Eliminate Cancer Initiative, a body with the ultimate goal to make cancer non-lethal for the next generation. Click to read full story



JUNE

A team led by Associate Professor Kevin Pfleger and colleagues in Melbourne awarded funds to develop a national training centre to fast track the translation of pioneering research into new medicines. Click to read full story

Discovered new way to examine how medicines act on cells.

Click to read full story

2017 MAJOR ACHIEVEMENTS



JULY

Funds awarded from the Cancer Research Trust to establish a world-class single cell genomic sequencing centre to transform cancer research in WA. Click to read full story

Positive results reported from

Perkins spinout company, Dimerix Limited, on clinical research into their chronic kidney disease treatment. Click to read full story



AUGUST

Study published by Associate Professor Aleksandra Filipovska linking faulty gene to obesity in adults. Click to read full story

A map of thousands of microRNAs and their gene expression published to help determine their role in cancer, cardiovascular disease, autoimmune disease and neurological disorders. Click to read full story



SEPTEMBER

New drug discovered by Professor Ruth Ganss to supercharge immune cells in the fight against cancer. Click to read full story



OCTOBER

Perkins researchers find new way to defend against Type 2 Diabetes. Click to read full story

6th annual MACA Ride to Conquer Cancer saw 855 riders raise \$4.1 million. Click to read full story



NOVEMBER

\$1.75 million awarded by the Australian Cancer Research Foundation for essential equipment to analyse tumour cell types. Click to read full story



DECEMBER

New evidence unearthed in a decade-long mystery concerning stem cell reprogramming. Click to read full story

BOARD OF DIRECTORS

Board meetings held | 7



Mr Laurence Iffla Chairman

Mr Iffla has been Non-Executive Director since March 2005 and Chairman of the Board since May 2009. He is a partner in the legal firm Iffla Wade and practices primarily in the area of commercial property law, State taxes and trusts, and joint ventures. Larry is the Non-Executive Deputy Chairman of Perron Group.

No. of meetings attended: 7



Professor
Peter J Leedman
Director

Professor Leedman took on the role of Director of the Perkins in early 2014. He is head of the Laboratory for Cancer Medicine, Professor of Medicine at The University of Western Australia, an endocrinologist at Royal Perth Hospital, and is Chairman of Linear Clinical Research Ltd. He is a graduate of the Australian Institute of Company Directors

No. of meetings attended: 7



Dr Stephen Davis

Dr Davis joined the Board in 2012. He is a Radiologist and Partner of Perth Radiological Clinic. He is a medical graduate of UWA, a Member of the Royal College of Physicians UK, and Fellow of the Australian and New Zealand College of Radiologists.

No. of meetings attended: 7



Mrs Jan Stewart PSM

Mrs Stewart joined the Board in February 2015. She held the position of CEO of Lotterywest from 1992 until December 2014. Mrs Stewart is a social worker by profession, having graduated from UWA with a Bachelor of Arts and a Master's Degree in Social Work. She is a graduate of the Australian Institute of Company Directors.

No. of meetings attended: 7

BOARD OF DIRECTORS

Board meetings held | 7



Mr Roger Port

Mr Port joined the Board in April 2015. He is Chairman of the Perkins Audit and Risk Committee. He is a chartered accountant and is a former partner in PricewaterhouseCoopers. He has 30 years' experience in financial analysis, company and business valuations, transaction due diligence and mergers and acquisitions, and led the PwC Perth Deals team for seven years. He is a Fellow of the Australian Institute of Company Directors.

No. of meetings attended: 7



Professor Dawn Freshwater Professor Dawn Freshwater joined the Board in June 2017. Professor Freshwater is the Vice-Chancellor of The University of Western Australia. Professor Freshwater serves on the Higher Education Funding Council for England's Research Excellence Framework panel, reviews and acts in an advisory capacity for the National Institute for Health Research and Medical Research Council and to the National Institute for Clinical Excellence.

No. of meetings attended: 2



Professor John Challis Retired in December 2017

Professor Challis joined the Board in June 2014 as proxy for the Vice-Chancellor of The University of Western Australia. He commenced his position as Pro Vice-Chancellor for Health and Medical Research in February 2014. In 2015, John took up the inaugural Director of the Western Australian Health Translation Network (WAHTN).

No. of meetings attended: 4



SUPPORTER ACKNOWLEDGEMENT

Thank you to our major benefactors and the many supporters who make our work possible.

BENEFACTORS

Wesfarmers Lotterywest MACA Limited

PIONEERS

Ashok & Renu Kumar and family Australian Cancer Research Foundation Estate of Alex Horan Hawaiian The Patterson Family The Stan Perron Charitable Trust Woodside

INNOVATORS

Cancer Council
Gina Rinehart
McCusker Charitable Foundation
Mineral Resources Limited
Prendiville Family

DISCOVERERS

Bev & Gordon Martin Colliers International Donna Boyd Dr Stephen Davis Fremantle Heart Institute Ian & Jill Green John Burt John & Mog Gadsdon Keli Sertorio Kristy Fogarty Macquarie Group Foundation Nicole Patterson Perth Radiological Clinic Foundation The Eddington Family The Kailis Foundation Tony Fini Foundation Wind Over Water Foundation

BUILDERS

Attilia & Frank Tomasi AXIS Financial Group Dr Bob Every AO & Sheryl Every Golden Group Pty Ltd Jamax Holdings Pty Ltd Julian Ambrose Massey Charitable Foundation MS & AC Gregg Patricia New Professor George Yeoh Regis Resources Ltd RJ Vincent and Co Ron Farris Real Estate Pty Ltd Tania & Clay Hollingsworth Tony Trevisan TRG Properties Pty Ltd Western Cardiology Windsor Knight Pty Ltd Zac Pearson Legacy

EXPLORERS

Adil Bux

Anne Pickett Bill & Barbara Busby Bridget Fave **BUX Foundation** Carlo Orlando Castelli Ptv Ltd Dr Mark & Kim Ireland Dr Nigel & Jeanette Sinclair Hardie Foundation Pty Ltd John McAlwey Mark & Louise Nidorf Max & Lorraine Kousins Michael Beech Mimi & Willy Packer Peter & Anne Hector Peter & Lynne Leonhardt Professor Peter Leedman Professor Peter Thompson AM RC Sports (WA) Pty Ltd Richard Lester AM Schaffer Corporation Ltd Security Capital Corporation Strzelecki Holdings Pty Ltd The Fero Group Tyler James Chong Gift Walter & Sue James Wendy Casey

ADVOCATES

Andrew & Jane Thompson

Barbara Bath Barbara Chandler Bert & Andrea Reuter Colin Cheng Collezione Bridal Couture David & Carol Bedbrook Dr F Gordon Stimson Dr Geoffrey K Lane Dr Joseph Glover Erich & Liz Fraunschiel Graham & Lyn Shields Hind's Sand Supplies John & Mog Gadsdon John Perry Keith & Gaye Kessell Magister Singh Pty Ltd Mark & Fiona Newman Michael Beech Napoli Chartered Accountants Neil McKerracher Pamela Pitt Paramount Safety Products Professor Joseph Hung Robert Black Stephen Jando The Carcione Foundation The Tong Foundation Pty Ltd Timothy Mack Wheatley Family Foundation

White Family Philanthropic Fund

COMPANIONS

Academy Café Anthony & Hendrika Chapman Beverley Fitzgerald Brasington Family Clough Limited CMP Products Pty Ltd Fiona Kemp Geraldton Yacht Club Gresham Partners Limits Harman Nominees Pty Ltd Heiko Plange Howard & Lindsay Read Jean Arkley JT Day Pty Ltd Linda Stewart-Richardson Mandurah Murray Mayday Club Mulloway Pty Ltd Offshore Plant Hire Pty Ltd Phillip Perry Prochem Pty Ltd Professor Ian Constable AO Professor S Dwivedi RJDO Fund Steve Dropulich Zap Nominees Pty Ltd Zento Global Solutions Pty Ltd

FRIENDS

Ann Ashbrook

Alan & Marisa Tribe

Alexandrea Thompson & Peter Smith

Anna Kemp Anthony Barton Bankwest Foundation Charles & Sylvia Bass Clinical Professor Turabali Chakera Cottesloe Golf Club Bell Ring Group Country Womens Association of WA – Kalamunda Denny Roberts Dr Donald Latchem Dr Jane Allen & Bradley Allen Dr Patricia Kailis Dr Peter James Dr Pradyot Saklani Eaton Corporation PLC Elizabeth Crosbie-Mahon Elizabeth Wetherell Emma Shand Hartleys Charity Committee Home Base Perth Howard & Lindsey Read Hugh Cunningham In loving memory of Leigh Smith Inner Wheel Club of Swan Valley Irwin and Berwine Barrett-Lennard James Thompson Jillian Brown Jim & Sandy Lane Jim & Freda Irenic Joan Lyons

Joan Newmark Joanna Shiel John & Jane Inverarity John & Mary Jo Lindquest John & Barbara Chandler John & Wendy Gardner John Cruickshank Joyner Family Endowment Klinger Ltd Larry & Nicola Iffla Lavan Lawrence Heavey Lesley Forgione Lions Club of Rockingham Louis Nilant Malcolm Lee QC Margaret Eyres Marion Anderson Mary Carr Michael & Josephine Ahern Michael Podkowka Ming Shang Cassim Murray Cutbush Neil Ferguson Neil Jensen Neil Patterson Patricia Slattery Patricia Tan Patrick Cooney Pindari Pty Ltd Professor Girish Dwivedi Property Bank Australasia R & J Moullin Raiu Batavia Robert Uppill Rosalind Clark Rotary Club of Western Endeavour Rotary Club of Willetton RTG Mining Inc Sara Wordsworth Schneider Electric Simon Diong Steven & Sook Molloy Sue Williams Suzette Branche Sydney Corser AM OBE & Danae Corser Symon Jenkins Toshiba (Australia) Pty Ltd Trevor Rock Trinity North Uniting Church -Night Craft Group Victa Golf Club Vivienne Dench Wavne S Martin

Women in Dentistry

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2017

REVENUE	2017 (\$)	2016 (\$)
Funding and grants – operating	3,386,815	3,374,393
Grants – capital works	_	21,124
Rendering of services – clinical billings	12,581,439	7,945,427
Donations	627,156	1,584,921
Event income	4,711,092	5,626,063
Facility income	6,064,698	6,143,091
Other income	965,888	896,484
Interest	478,958	529,982
	28,816,046	26,121,486
EVENCES		
EXPENSES		
Employee costs	(6,410,897)	(6,977,889)
Laboratory and clinical expenditure	(5,747,555)	(5,175,988)
Cost of sales – clinical billings	(8,067,187)	(3,571,806)
Depreciation	(7,553,109)	(7,850,883)
Administration, office, event and utilities expenditure	(9,083,741)	(0.440.700)
Net deficit		(9,410,708)
Net deficit	(8,046,443)	(9,410,708) (6,865,788)
Other comprehensive income / (loss)	(8,046,443) 110,106	

The Statement of Comprehensive Income provided, together with the attached Statement of Financial Position, have been extracted from the audited special purpose financial statements of the Harry Perkins Institute of Medical Research and its controlled entities. The summary financial information does not include all the information and notes normally included in an audited financial report. The audited special purpose financial report can be obtained upon request to the Chief Financial Officer.

The audited financial report (from which the summary financial information has been extracted) has been prepared in accordance with the requirements of the Associations Incorporation Act 2015, Australian Charities and Not-for-profits Commission Act 2012 and Regulations 2013, Australian Accounting Standards and other authoritative pronouncements of the Australian Accounting Standards Board.

STATEMENT OF FINANCIAL POSITIONFOR THE YEAR ENDED 31 DECEMBER 2017

CURRENT ASSETS	2017 (\$)	2016 (\$)
Cash and cash equivalents	25,654,753	29,154,750
Cash held in trust	_	3,948
Trade and other receivables	4,972,302	3,629,474
Inventory	2,858	7,425
Prepayments	260,141	240,183
Held-to-maturity investments	3,943,525	_
TOTAL CURRENT ASSETS	34,833,579	33,035,780
NON-CURRENT ASSETS		
Investments	2,254,918	1,144,060
Property, plant and equipment	124,104,383	131,042,644
TOTAL NON-CURRENT ASSETS	126,359,301	132,186,704
TOTAL ASSETS	161,192,880	165,222,484
CURRENT LIABILITIES		
Trade and other payables	8,006,164	5,090,907
Grants held in trust	13,685,396	12,557,168
Non interest-bearing liabilities	225,000	225,000
Employee entitlements	748,452	697,162
TOTAL CURRENT LIABILITIES	22,665,012	18,570,237
NON-CURRENT LIABILITIES		
Non interest-bearing liabilities	280,397	505,397
Employee entitlements	160,565	123,607
TOTAL NON-CURRENT LIABILITIES	440,962	629,004
TOTAL LIABILITIES	23,105,974	19,199,241
NET ASSETS	138,086,906	146,023,243
Accumulated surplus	137,903,635	145,950,078
Available for sale revaluation reserve	183,271	73,165
TOTAL SURPLUS	138,086,906	146,023,243

THANK YOU FOR HELPING US TO KEEP FAMILIES TOGETHER FOR LONGER

OUR PROMISE TO YOU

Without **you**, the Perkins would cease to exist.

We value you – your opinion, your financial contribution and your friendship.

OUR DISEASE FOCUS

IN SUPPORTING YOU, WE WILL ALWAYS BE:



Heart Disease

GENUINE

You can trust that your donation will be used to support better health outcomes for you and your family.



Cancer

TRUTHFUL

Your contributions will support where there is the greatest need, unless otherwise directed by you.



Diabetes

APPRECIATIVE

We don't take your friendship for granted. We will listen to what you have to say and respect your wishes.



Rare Genetic Diseases

PROTECTIVE

Your personal information is private. Your details are protected and not shared with other charitable causes.



Get in touch

To contact our donor relations team, call us on (08) 6151 0772 or email us at partner@perkins.org.au.

RESPECTFUL

You play a role in our achievements. We will always share the impact of your generosity.